DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.51
-0.10 (-1.51%)
Feb 21, 2025, 4:00 PM EST - Market closed
DiaMedica Therapeutics Employees
As of December 31, 2023, DiaMedica Therapeutics had 19 total employees, including 18 full-time and 1 part-time employees. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$1,142,368
Market Cap
278.37M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
DMAC News
- 2 days ago - DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke - Business Wire
- 11 days ago - DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 2 months ago - DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia - Business Wire
- 3 months ago - DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results - Business Wire
- 3 months ago - DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
- 3 months ago - DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference - Business Wire
- 3 months ago - DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 - Business Wire